GYRE - GYRE THERAPEUTICS, INC.
7.94
-0.160 -2.015%
Share volume: 50,625
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$8.10
-0.16
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-13-2024 | 08-13-2024 | 11-13-2024 | 03-17-2025 | 05-09-2025 | 08-11-2025 | 11-07-2025 | 03-13-2026 | |
| Total revenue | 27.172 M | 25.225 M | 25.488 M | 27.872 M | 22.058 M | 26.771 M | 30.564 M | 37.195 M | |
| Cost of revenue | 979.000 K | 770.000 K | 958.000 K | 1.177 M | 894.000 K | 1.151 M | 1.628 M | 1.743 M | |
| Gross profit | 26.193 M | 24.455 M | 24.530 M | 26.695 M | 21.164 M | 25.620 M | 28.936 M | 35.452 M | |
| -6.64% | 0.31% | 8.83% | -20.72% | 21.05% | 12.94% | 22.52% | |||
| Operating expenses | 5.580 M | 6.779 M | 6.598 M | 9.176 M | 8.050 M | 8.254 M | 6.682 M | 11.516 M | |
| Selling general and admin | 3.398 M | 3.424 M | 3.823 M | 5.464 M | 4.955 M | 4.829 M | 4.319 M | 6.701 M | |
| Research and development | 2.182 M | 3.355 M | 2.775 M | 3.712 M | 3.095 M | 3.425 M | 2.363 M | 4.815 M | |
| Total expenses | 18.122 M | 21.261 M | 20.297 M | 26.030 M | 18.891 M | 23.449 M | 22.011 M | 35.334 M | |
| 17.32% | -4.53% | 28.25% | -27.43% | 24.13% | -6.13% | 60.53% | |||
| Operating income | 8.071 M | 3.262 M | 4.233 M | 597.000 K | 2.273 M | 2.171 M | 6.925 M | 118.000 K | |
| Ebit | 12.153 M | 5.753 M | 3.407 M | 358.000 K | 4.635 M | 2.238 M | 7.629 M | -1.813 M | |
| Pretax income | 12.481 M | 6.035 M | 3.930 M | 772.000 K | 4.635 M | 2.238 M | 7.629 M | -66.000 K | |
| -51.65% | -34.88% | -80.36% | 500.39% | -51.72% | 240.88% | -100.87% | |||
| Income tax | 2.546 M | 1.497 M | 1.074 M | 203.000 K | 901.000 K | 662.000 K | 1.693 M | 1.300 M | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | 9.935 M | 4.538 M | 2.856 M | 569.000 K | 3.734 M | 1.576 M | 5.936 M | -1.366 M | |
| -54.32% | -37.06% | -80.08% | 556.24% | -57.79% | 276.65% | -123.01% |